Zacks Research Boosts Earnings Estimates for Henry Schein

Henry Schein, Inc. (NASDAQ:HSIC) – Equities researchers at Zacks Research raised their FY2024 earnings estimates for shares of Henry Schein in a report issued on Tuesday, November 26th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $4.76 for the year, up from their previous forecast of $4.73. The consensus estimate for Henry Schein’s current full-year earnings is $4.78 per share. Zacks Research also issued estimates for Henry Schein’s Q4 2024 earnings at $1.21 EPS, Q1 2025 earnings at $1.17 EPS, Q2 2025 earnings at $1.28 EPS, Q3 2025 earnings at $1.31 EPS, Q4 2025 earnings at $1.40 EPS, FY2025 earnings at $5.15 EPS, Q1 2026 earnings at $1.35 EPS, Q2 2026 earnings at $1.39 EPS and FY2026 earnings at $5.61 EPS.

A number of other brokerages have also recently weighed in on HSIC. Robert W. Baird cut their price objective on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Evercore ISI upped their price target on shares of Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 8th. StockNews.com upgraded shares of Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Barrington Research reissued an “outperform” rating and set a $82.00 target price on shares of Henry Schein in a report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. decreased their price target on Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Six research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $79.38.

Henry Schein Trading Down 0.8 %

Shares of HSIC stock opened at $77.05 on Thursday. Henry Schein has a 1 year low of $63.67 and a 1 year high of $82.63. The firm has a market capitalization of $9.61 billion, a PE ratio of 31.96, a price-to-earnings-growth ratio of 2.23 and a beta of 0.87. The stock has a fifty day moving average of $71.36 and a two-hundred day moving average of $69.89. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.05. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.24 billion. During the same quarter in the previous year, the company posted $1.32 earnings per share. The business’s revenue for the quarter was up .4% compared to the same quarter last year.

Institutional Trading of Henry Schein

Institutional investors have recently made changes to their positions in the stock. ING Groep NV purchased a new stake in Henry Schein in the 3rd quarter worth approximately $63,226,000. Holocene Advisors LP acquired a new position in shares of Henry Schein in the third quarter worth $58,319,000. Thompson Siegel & Walmsley LLC purchased a new stake in shares of Henry Schein during the second quarter worth $46,683,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Henry Schein during the third quarter valued at $43,740,000. Finally, Southpoint Capital Advisors LP grew its stake in Henry Schein by 30.0% in the third quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company’s stock valued at $189,540,000 after purchasing an additional 600,000 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Lorelei Mcglynn sold 21,035 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $69.30, for a total value of $1,457,725.50. Following the completion of the sale, the senior vice president now owns 71,833 shares in the company, valued at $4,978,026.90. This represents a 22.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael S. Ettinger sold 12,240 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $75.00, for a total value of $918,000.00. Following the completion of the sale, the chief operating officer now directly owns 87,706 shares of the company’s stock, valued at approximately $6,577,950. This trade represents a 12.25 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by company insiders.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.